In 2010 the antiapoptotic, neuroprotective aminopropyl carbazole agent P7C3 was discovered using a novel in-vivo screening approach 1. It has been proposed that the compound exerts its actions by activating the enzyme nicotinamide phosphoribosyltransferase (NAMPT). NAMPT is the rate-limiting enzyme in the nicotinamide adenine dinucleotide (NAD) salvage pathway that converts nicotinamide to nicotinamide mononucleotide (NMN), the precursor to NAD synthesis (Fig. 1). The NAD salvage pathway is important in Wallerian degeneration (WD), the active degeneration of an axon or neurite distal to a site of injury. P7C3, and one of its more active fluorinated enantiomers P7C3-A20, has shown promise as a therapeutic agent in a number of conditions that have been associated with WD. It was capable of blocking 1-methyl-4phenyl-1,2,3,4-tetrahydropyridine-induced death of dopaminergic substantia nigra cells in an adult mouse model of Parkinson’s disease 2. Its ability to protect spinal motor neurons from cell death was demonstrated both histologically and functionally in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis 3. The potential for benefit of P7C3 derivatives in traumatic brain injury (TBI) was indicated by the findings that the analogue P7C3-S243, prevented retinal ganglion cell loss following experimental blast injury in mice 4. This was followed by a demonstration that P7C3-S243 also ameliorated behavioural deficits, including motor, learning, memory loss and axon loss in the CA1 stratum radiatum region of blast injury exposed mice 5. Furthermore, P7C3-A20 administration in a rat fluid-percussion injury model showed a reduction in contusion volume and improved sensorimotor and cognitive function 6.
The in-vivo phenotypic screening method by which the P7C3 compounds were discovered meant that further work has been required to elucidate their mode of action. Subsequent research has shown that P7C3-related compounds have some NAMPT-activating activity. NAMPT is an important enzyme in the WD pathway. However, the ability of NAMPT activation to protect against WD is not established and it has not been definitively shown that NAMPT activation is the means by which P7C3-based compounds exert their therapeutic action, or that they do not have other actions.
Materials and methods
Mouse origin and cell culture
C57BL/6 wild-type and SARM1−/− mice were obtained from Babraham Institute (Babraham, UK). C57BL/6OlaHsd-Wlds (Wlds) mice, originally obtained from Harlan (Bicester, UK), were maintained as a separate colony at the Babraham Institute for 13 years. All animal work was performed in accordance with the 1986 Animals (Scientific Procedures) Act under project licence PPL 70/7620. All superior cervical ganglion explant (SCGe) and dissociated superior cervical ganglion (dSCG) cultures were obtained from humanely killed postnatal day 0 (P0) to P2 mice and were prepared as described previously 7,8. Cells were cultured for 7 days in vitro before experimentation. SCGe were plated on 35 mm Nunc cell culture dishes (Thermo-Fisher Scientific, Waltham, Massachusetts, USA), and dSCGs were plated on low 35 mm μ-dishes (ibidi, Martinsried, Germany). Primary cortical neuronal cells were extracted by dissecting out a section of cortical mantle, trypsinizing and dissociating the neurons before separating by centrifugation. Viability was confirmed to be greater than 95%. The cells were then plated and cultured on low 35 mm μ-dishes (ibidi) for 7 days in vitro before experimentation. In all cases, dishes were coated with poly-L-lysine (25 μg/ml; Sigma, St. Louis, Missouri, USA), then laminin (2 μg/cm2; Sigma). All cultures were maintained in an incubator at a constant 37°C with 5% CO2.
The compound P7C3-A20 (cat no. 2850) was sourced from Cambridge Bioscience (Cambridge, UK) and supplied by Biovision (Milpitas, California, USA) and prepared and used according to manufacturer’s instructions.
Transection and imaging
Transection injury of SCGes was undertaken by a single linear incision made 2 mm from the cell mass with a #10 blade scalpel (Swann-Morton, Sheffield, UK). All images of SCG and primary cortical neuron (PCN) cultures were taken on an Olympus IX81 inverted microscope system (Olympus, Shinjuku, Tokyo, Japan) using ×20 magnification and phase-contrast imaging.
Neurite degeneration index
The neurite degeneration index (NDI) is an established quantitative measure of neurite degeneration (ND) 9. Images of the same, or similar, the field of neurites are obtained at different time points or treatment conditions at a controlled level of magnification (×20) and illumination. In the case of SCGe the imaged field is typically 5 mm from the main explant mass where the density of the neurites allows clear visualization of morphological change. The NDI is calculated by an Image J (University of Wisconsin, Wisconsin, USA) plug-in algorithm that is operator independent. The output is a unitless number from 0 to 1 based on the degree of neurite continuity or fragmentation. Most healthy neurites score around 0.1–0.3, whereas a profoundly degenerated field would be in the range of 0.6–0.9. In the case of complete degeneration, with or without detachment, a score of 0.9 is assigned 9.
Levels of NAD were measured using the NAD/NADH-Glo assay (Promega, Madison, Wisconsin, USA). The assay was performed according to the manufacturer’s protocol. The assay contains a cycling reductase enzyme that reduces a proluciferin reductase substrate to luciferin in the presence of NADH. Luminescence signals were measured by PHERAstar plate reader (BMG Labtech, Ortenberg, Germany).
Data are expressed as a mean value with error bars representing SEM unless otherwise stated. A number of repeats and replicates and statistical tests are detailed in each figure legend. A P value of 0.05 or less was considered significant for any data set. Asterisks represent the statistical significance as follows: *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001, P<0.05 (NS). All statistical tests and graphs were generated with GraphPad Prism Software, version 7.0 (GraphPad Software Inc., La Jolla, USA).
To select an appropriate concentration of P7C3-A20 to test in WD, we first assessed for toxicity over a wide concentration range (50 nm to 10 μM) in a variety of neuronal cell types (Fig. 2). P7C3-A20 induces spontaneous ND, as measured by the NDI 6, in a concentration-dependent manner in murine SCGe, SCGd and PCN cultures but concentrations of 100 nM or below were found to cause no toxicity at the 24-h timepoint. The ND at concentrations above 100 nM might follow a Wallerian-like mechanism following activation of NAMPT leading to overproduction of NMN. To test this possibility, we asked whether SCGe cultures from SARM1−/− and Wlds mice showed any less ND at a 10 μM concentration of P7C3-A20, a concentration that we demonstrated induced ND within 6 h (Fig. 3). In both SARM1−/− and Wlds cultures, the degeneration was rapid and comparable to wild-type cultures. This suggests the mechanism of degeneration at high concentrations of P7C3-A20 is independent of the WD pathway.
We then tested whether 100 nM P7C3-A20 was able to rescue NAD depletion caused by doxorubicin in these neuronal types, as was previously reported for human bone osteosarcoma epithelial (U2OS) cells 10 (Fig. 4). Doxorubicin-treated PCN and SCGe cultures showed a reduction in NAD levels as measured by a luciferin based (NAD+NADH) assay. This was from an average of 395 485 to 131 406 relative light units in PCN (66.8% reduction, P≤0.001), and 590892 to 170363 relative light units in SCGe (71.2% reduction, P<0.01). When doxorubicin-exposed cells were co-treated with P7C3-A20, there was a partial rescue in NAD levels in PCN cultures with an average output of 263 886 relative light units; a 34.4% greater maintenance of NAD levels than seen in untreated cultures (P≤0.001). However, P7C3-A20 did not rescue the NAD level in SCGs treated with doxorubicin; these had an average output of 200 318 relative light units. This was not significantly different than the average 170 363 light units seen in SCGs treated with doxorubicin alone. While we cannot rule out loss or degradation of NAD from doxorubicin-treated SCGs, this failure to rescue the NAD levels in SCGs suggests the ability of P7C3-A20 to activate NAMPT may not be conserved across all neuronal cell types.
Neurite transection of untreated wild-type SCGe cultures resulted in a progressively increased ND at 6 h – with a precut degeneration index average of 0.70 and a 6 h post cut index of 0.67 (P≤0.0001) (Fig. 5). When pretreated with P7C3-A20 2 h before transection, or immediately before the transection, there was no significant difference in the degree of WD between the untreated and treated cultures (average of 0.70 for pretreated and 0.76 for those treated at time of cut), hence indicating that the reported neuroprotective effects of P7C3-A20 are unlikely to be mediated by a delay in WD.
In dispersed PCN cultures, neurite length and growth patterns make their physical transection unreliable, so Wallerian-like degeneration was induced with a 100-nM concentration of vincristine (Fig. 6). Baseline ND scores in untreated control PCN were an average of 0.3. Six hours after treatment with vincristine these rose to 0.78 (P≤0.0001). Unlike Wlds and knockout of SARM1 11,12, co-treatment of cultures with P7C3-A20 in addition to vincristine did not prevent ND with an average NDI of 0.82.
The drug P7C3-A20 has shown promise in various animal models of neurological disease, including TBI 6, chronic visual deficits 4, Parkinson’s disease 2 and amyotrophic lateral sclerosis 13. It has also been suggested as a possible therapeutic agent for other neurodegenerative diseases including Alzheimer’s disease, and as a preserver of cognitive capacity in aging 1,13. P7C3-A20 has been shown to enhance neuron formation in the subgranular zone of the dentate gyrus of adult mice and protected against apoptotic loss of newborn hippocampal neurons in neuronal PAS domain protein 3 knockout mice 1.
The in-vivo phenotypic screen by which the P7C3 compounds were discovered meant that further work was required to elucidate their mode of action. This involved triggering the death of human osteosarcoma (U2OS) cells using eight toxic compounds and testing whether P7C3 could rescue any of these. In this way, doxorubicin toxicity was found to cause P7C3 sensitive cell death. Doxorubicin is a commonly used chemotherapeutic agent that acts through a mechanism involving intracellular depletion of NAD. NAD was partially restored in a concentration-dependent manner by U2OS cell treatment with P7C3 enantiomers. A photocrosslinking approach followed by click chemistry with Alexa 532 dye then showed that P7C3 bound to NAMPT. These findings suggested that P7C3 activity might be related to NAMPT activation and related NAD preservation. This theory is particularly intriguing as NAMPT and NAD are key molecular players in WD, the process by which an axon or neurite degenerates distal to a site of injury. The active degeneration of WD occurs in both central and peripheral neurons, including PCNs, and may be an important component of several pathological entities including many neurodegenerative disorders, neuropathies and TBI 14. WD is now recognized as an active cell-autonomous death pathway.
To progress from animal models to human trials, it is important to have a thorough understanding of the mechanistic effects of a drug. This study was undertaken to further characterize the mechanism of P7C3-A20 action and to explore the proposition that its effects are because of NAMPT activation leading to protection against WD. Several key steps in the WD pathway have been identified including loss of the enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2), for example, in distal neurites because of interrupted delivery from the soma following transection injury or transport block 15,16. Ordinarily, NMNAT2 is produced in the cell soma and shuttled by kinesin-mediated axonal transport to distal neurites. Lack of NMNAT2 results in an inability to convert NMN to NAD. This leads to a rise in NMN and fall in NAD levels in the distal axon, and is then followed by a step dependent on sterile-alpha and TIR motif containing protein 1 (SARM1) molecule and subsequent calcium-mediated axonal fragmentation 17. SARM1 is a Toll-like receptor adaptor protein that is a major player in WD when it is knocked out there the result is delayed WD. A related spontaneous slow-WD mutation ‘Wlds’ phenotype exists where animals have a long-acting NMNAT2 like protein ‘WLDs’ that can substitute for lost NMNAT2 and delay the active WD process. Another important enzyme in the WD pathways is NAMPT. The role of NAMPT in WD can be demonstrated through the use of the NAMPT inhibitor FK866; this blocks the conversion of nicotinamide to NMN. When murine SCGe neurons were pretreated with FK866 up to a day before, or up to 3 h after, transection injury, they showed a delayed WD phenotype for 24–48 h. However, after 96 h even uninjured neurites spontaneously degenerated 9. The initial delay in WD may have been due to a reduction in NMN accumulation as the addition of exogenous NMN could revert protection by FK866. Their eventual degeneration may be caused by NAD depletion and cellular energetic failure.
P7C3-A20 has previously been shown to increase NAD levels in U2OS cells; following this, we found it was able to increase NAD levels in selected primary neuronal cell types. Furthermore, no protection against WD was found in any cell type, regardless of whether the injury was physical transection or by vincristine. Vincristine is a chemotherapeutic drug that causes a length-dependent axon degeneration 18. This degeneration is blocked by Wlds or removal of SARM1 1,11,19. Hence, vincristine is an example of an exogenous chemical agent that can be used to trigger Wallerian-like degeneration without the requirement for a physical injury.
The ability of NAMPT to catalyze the metabolism of nicotinamide to NMN raises intriguing questions about how P7C3 may influence WD. As long as NMNAT2 is present in the axon, it will use NMN to synthesize NAD, but after axon injury, NMNAT2 is rapidly degraded 10,11 and NMN accumulates 6. Increasing NAMPT activity after cutting axons would be expected to lead to faster accumulation of NMN and thus might increase the rate of degeneration. In studies where NAMPT expression was instead reported to be protective, its expression was increased before axons were cut 20. The ability of NAMPT inhibition to delay WD contrasts with the proposed action of P7C3-A20 to block cell death mechanisms through augmenting NAMPT activity. To resolve this, we tested the effect of P7C3-A20 on the survival of both injured and intact axons. We found that P7C3-A20 was unable to prevent doxorubicin-induced death or to delay WD in either primary neuronal culture or superior cervical ganglion cell cultures. Therefore, any therapeutic benefits of the compound may act through different mechanistic pathways.
Our findings did not support a proposed mechanism of P7C3-A20 as a NAMPT activator leading to protection against WD. This suggested that P7C3-A20’s mechanism of action needs further investigation. Its failure to protect against WD suggests that it might not be an appropriate agent to treat diseases that have a large WD-like component, for example, chronic inflammatory peripheral neuropathy, glaucoma and some forms of hereditary motor sensory neuropathy.
A further finding was the concentration-related toxicity of P7C3-A20. It has previously been reported in rodent models to have a wide-therapeutic index 10. In our study, we found that there was a marked concentration-dependent toxicity in all primary neuronal cultures. The failure of Wlds and SARM1 knockout transgenics to protect against this suggests that it is due to a mechanism independent of WD. This toxicity needs to be better understood, both in its mechanism, in an in-vitro setting and in the design of any human clinical trials.
The antiapoptotic, neuroprotective agent P7C3-A20 caused ND at concentrations of 500 nM or greater in dSCG, SCGe and PCN. At concentrations of 100 nM, P7C3-A20 was able to partially rescue doxorubicin-induced NAD depletion in PCN, but not in SCGe. P7C3-A20 failed to delay WD induced by transection in SCGe, or by vincristine in dissociated PCN. These findings are significant in understanding the consequences of exposing neurons to various concentrations of P7C3-A20 and identifying the mechanisms by which the compound exerts its action. Additional investigation of the mechanistic action of P7C3-A20 is required to build the necessary foundation for potential human studies.
The authors thank Dr Jon Gilley and Dr Claire Harwell for their support and advice during the preparation of this manuscript.
C.S.H. is supported by a Wellcome Trust PhD for Clinicians.
D.K.M. is supported by a Senior Investigator Award from the National Institute for Health Research, UK (NIHR), by the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, and a Framework Program 7 grant from the European Union (CENTER-TBI; Grant no: 602150).
M.P.C. is funded by the John and Lucille van Geest Foundation.
Conflicts of interest
There are no conflicts of interest.
1. Pieper AA, Xie S, Capota E, Estill SJ, Zhong J, Long JM, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell 2010; 142:39–51.
2. De Jesús-Cortés H, Xu P, Drawbridge J, Estill SJ, Huntington P, Tran S, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci USA 2012; 109:17010–17015.
3. Tesla R, Wolf HP, Xu P, Drawbridge J, Estill SJ, Huntington P, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2012; 109:17016–17021.
4. Dutca LM, Stasheff SF, Hedberg-Buenz A, Rudd DS, Batra N, Blodi FR, et al. Early detection of subclinical visual damage after blast-mediated TBI enables prevention of chronic visual deficit by treatment with P7C3-S243. Invest Ophthalmol Vis Sci 2014; 55:8330–8341.
5. Yin TC, Britt JK, De Jesús-Cortés H, Lu Y, Genova RM, Khan MZ, et al. P7C3 neuroprotective chemicals block axonal degeneration and preserve function after traumatic brain injury. Cell Rep 2014; 8:1731–1740.
6. Blaya MO, Bramlett HM, Naidoo J, Pieper AA, Dietrich WD. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. J Neurotrauma 2014; 31:476–486.
7. Gilley J, Coleman MP. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol 2010; 8:e1000300.
8. Gilley J, Adalbert R, Yu G, Coleman MP. Rescue of peripheral and CNS axon
defects in mice lacking NMNAT2. J Neurosci 2013; 33:13410–13424.
9. Di Stefano M, Nascimento-Ferreira I, Orsomando G, Mori V, Gilley J, Brown R, et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon
degeneration. Cell Death Differ 2014; 22:731–742.
10. Wang G, Han T, Nijhawan D, Theodoropoulos P, Naidoo J, Yadavalli S, et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 2014; 158:1324–1334.
11. Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J. Sarm1-mediated axon
degeneration requires both SAM and TIR interactions. J Neurosci 2013; 33:13569–13580.
12. Watanabe M, Tsukiyama T, Hatakeyama S. Protection
of vincristine-induced neuropathy by Wld S expression and the independence of the activity of Nmnat1. Neurosci Lett 2007; 411:228–232.
13. Pieper AA, McKnight SL, Ready JM. P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. Chem Soc Rev 2014; 43:6716–6726.
14. Conforti L, Gilley J, Coleman MP. Wallerian degeneration
: an emerging axon
death pathway linking injury and disease. Nat Rev Neurosci 2014; 15:394–409.
15. Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem 2005; 280:36334–36341.
16. Milde S, Gilley J, Coleman MP. Subcellular localization determines the stability and axon
protective capacity of axon
survival factor Nmnat2. PLoS Biol 2013; 11:e1001539.
17. Wang JT, Medress ZA, Barres BA. Axon
degeneration: molecular mechanisms of a self-destruction pathway. J Cell Biol 2012; 196:7–18.
18. Wang M-S, Wu Y, Culver DG, Glass JD. Pathogenesis of axonal degeneration: parallels between Wallerian degeneration
and vincristine neuropathy. J Neuropathol Exp Neurol 2000; 59:599–606.
19. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004; 305:1010–1013.
20. Sasaki Y, Araki T, Milbrandt J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci 2006; 26:8484–8491.
Keywords:© 2018 Wolters Kluwer Health | Lippincott Williams & Wilkins
axon; P7C3-A20; protection; Wallerian degeneration